Wagner H N
Division of Nuclear Medicine and Radiation Health Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21205-2179, USA.
J Nucl Med. 1995 Jun;36(6 Suppl):2S-4S.
Molecular nuclear medicine can image in vivo biochemistry. Studies with receptor-based radiopharmaceuticals provide windows to the biochemical processes of proteins as they carry out instructions from genetic coding. The patient's genotype determines this biochemical expression of phenotype. Radiotracer studies that visualize in vivo biochemistry provide a glimpse at a patient's "chemotype." Molecular nuclear medicine enables us to connect genotype to phenotype via chemotype. Diagnostic medicine will move past the point of grouping patients according to clinical signs and symptoms. More and more, diseases will be viewed as biochemical processes rather than the clinical manifestations of those processes. Today, there are examples of molecular nuclear medicine studies that affect medical decision-making.
分子核医学能够对体内生物化学过程进行成像。基于受体的放射性药物研究为蛋白质执行遗传编码指令时的生化过程提供了观察窗口。患者的基因型决定了这种表型的生化表达。可视化体内生物化学过程的放射性示踪剂研究让我们得以一窥患者的“化学型”。分子核医学使我们能够通过化学型将基因型与表型联系起来。诊断医学将超越根据临床体征和症状对患者进行分组的阶段。越来越多的疾病将被视为生化过程，而非这些过程的临床表现。如今，已有一些分子核医学研究实例影响着医疗决策。
